603963 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Dali Pharmaceuticalco.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.31 |
| 52 Week High | CN¥15.97 |
| 52 Week Low | CN¥2.28 |
| Beta | 0.12 |
| 11 Month Change | 10.70% |
| 3 Month Change | -5.43% |
| 1 Year Change | -69.77% |
| 33 Year Change | -54.41% |
| 5 Year Change | -65.63% |
| Change since IPO | -59.87% |
Recent News & Updates
Shareholder Returns
| 603963 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.8% | 0.5% | -0.8% |
| 1Y | -69.8% | -12.3% | -13.4% |
Return vs Industry: 603963 underperformed the CN Pharmaceuticals industry which returned -12.3% over the past year.
Return vs Market: 603963 underperformed the CN Market which returned -13.4% over the past year.
Price Volatility
| 603963 volatility | |
|---|---|
| 603963 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.8% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 603963's share price has been volatile over the past 3 months.
Volatility Over Time: 603963's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 272 | Jun Xiang Yang | www.daliyaoye.cn |
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company’s products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections.
Dali Pharmaceuticalco.,Ltd Fundamentals Summary
| 603963 fundamental statistics | |
|---|---|
| Market cap | CN¥727.21m |
| Earnings (TTM) | -CN¥21.40m |
| Revenue (TTM) | CN¥55.11m |
13.2x
P/S Ratio-34.0x
P/E RatioIs 603963 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603963 income statement (TTM) | |
|---|---|
| Revenue | CN¥55.11m |
| Cost of Revenue | CN¥42.68m |
| Gross Profit | CN¥12.43m |
| Other Expenses | CN¥33.83m |
| Earnings | -CN¥21.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 22.55% |
| Net Profit Margin | -38.84% |
| Debt/Equity Ratio | 5.2% |
How did 603963 perform over the long term?
See historical performance and comparison